

**LISTING OF CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application. In the amended claims, additions are shown as underlined and deletions are shown as ~~struckthrough~~.

1. (Currently Amended) A controlled release system, comprising 4-10 wt% 3-10wt% of temozolomide and biodegradable polyanhydrides, wherein the controlled release system releases temozolomide for a period ranging from 6 hours to 4 weeks *in vivo* polymeric materials.
2. (Original) The controlled release system according to claim 1, which is implantable tablet.
3. (Canceled)
4. (Canceled)
5. (Currently Amended) The controlled release system according to claim 1 ~~claim 4~~, wherein the polyanhydrides are said poly(anhydride) is one condensed from 1,3-bis(p-carboxyphenoxy) propane 3,4-bis(p-carboxyphenoxy) propane (CPP) and sebacic acid (SA).
6. (Canceled)
7. (Currently Amended) A process of preparing the temozolomide controlled release tablets, comprising:
  - a. Dissolving the polyanhydrides ~~polymeric materials~~ in a solvent to give a solution of polyanhydrides ~~polymeric materials~~;

- b. Dispersing temolozomide in or mixing temolozomide with the said solution of polyanhydrides ~~polymeric materials~~ to produce a mixture of polyanhydrides ~~polymeric materials~~ and temolozomide;
  - c. Spray-drying the said mixture of polyanhydrides ~~polymeric materials~~ and temolozomide to obtain microspheres; and
  - d. Tableting the said microspheres to obtain implantable tablets;  
wherein the controlled release system releases temozolomide for a period ranging from 6 hours to 4 weeks *in vivo*.
8. (Canceled)
9. (Canceled)
10. (Currently Amended) The process according to claim 7, wherein the ~~said~~ solvent in step (a) is methylene chloride.
11. (Currently Amended) A process of preparing the temozolomide controlled release tablets, comprising:
- a. Dissolving the polyanhydrides ~~polymeric materials~~ in a solvent to give a solution of polyanhydrides ~~polymeric materials~~;
  - b. Adding temolozomide into the said solution of polyanhydrides ~~polymeric materials~~ and ultrasonic-emulsifying the resultant solution to obtain a first emulsion;
  - c. Mixing the said first emulsion with polyvinyl alcohol (PVA), followed by evaporating the solvent to obtain hard microspheres;
  - d. Eliminating PVA and residual solvent by washing with water to obtain microspheres; and
  - e. Tableting the said microspheres to obtain implantable tablets;  
wherein said controlled release system releases temozolomide for a period ranging from 6 hours to 4 weeks *in vivo*.

12. (Canceled)
13. (Canceled)
14. (Currently Amended) The process according to claim 11, wherein the ~~said~~ solvent in step (a) is methylene chloride.